Molbio Diagnostics Targets ₹940 Crore Through IPO for Expansion

Molbio Diagnostics, a leader in molecular diagnostics, is preparing to launch an initial public offering (IPO) aimed at raising ₹940 crore. The company seeks to secure ₹200 crore through a fresh issue of shares to bolster its capital expenditures. Additionally, it plans to generate ₹740 crore via an offer for sale, which will decrease the promoter group's stake from 46.6% to 43%.

Global Reach and Revenue Growth

Founded in 2000, Molbio Diagnostics has established a robust presence worldwide, operating six manufacturing facilities across India and serving clients in over 90 countries. The company caters to diverse sectors, including government health programs, diagnostic laboratories, hospitals, and international healthcare organizations.

The company’s revenue has been significantly bolstered by its tuberculosis diagnostic test kits, which account for 70% of its test kit sales. Overall, test kits contribute to 74% of Molbio’s revenue. The firm’s innovative 'Truenat' platform, a portable diagnostic system designed for resource-limited settings, provides rapid and accurate test results within an hour, covering over 30 diseases with 43 diagnostic assays.

Financial Performance and Market Position

Molbio Diagnostics has demonstrated strong financial growth, with revenue from operations increasing by 31.5% annually to ₹1,445.7 crore between FY24 and FY26. During the same period, net profit rose by 40.2% to ₹164.1 crore, and EBITDA grew by 33.2% to ₹328.2 crore, with the EBITDA margin improving to 22.6% in FY26 from 22% in FY24.

In FY26, the company experienced a 41.7% year-on-year revenue jump, with EBITDA and net profit increasing by 27.9% and 18.4%, respectively. Despite the lack of directly comparable listed peers in India, Molbio's P/E ratio stands at up to 57, aligning with other healthcare diagnostics and medical device companies such as Poly Medicure and Dr. Lal PathLabs, which trade at P/E multiples between 54 and 81.

Investment Considerations for High-Risk Investors

High-risk investors may find the Molbio Diagnostics IPO appealing due to the company's solid financial growth and innovative product offerings. The firm's focus on infectious and non-communicable disease diagnostics, along with its strategic collaborations, positions it well for future expansion. However, potential investors should be aware of the customer concentration risk, as over half of the company’s revenue is derived from its top clients.

The IPO proceeds will enable Molbio to enhance its operational infrastructure and potentially expand its market share, providing a growth opportunity for investors willing to navigate the associated risks.